CompanyPRAXNasdaqBoston, MA

Praxis Precision Medicines

Praxis Precision Medicines develops small molecules and antisense oligonucleotides for CNS disorders characterized by neuronal excitation-inhibition imbalance, including epilepsy and movement disorders.

Stories only

SEC EDGAR ClinicalTrials.gov praxismedicines.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 6Latest story

August 2026

Praxis reports Q2 2026 results, mid-cycle FDA meetings clear for two lead drugs

Aug 6Quarterly updatePraxis Precision Medicines